Author name: DrugChatter

Spend enough time watching patient questions, and a pattern emerges: it’s not just “does this work?” or “is this safe?”—it’s […]

If you want to understand drug shortages, don’t start with FDA dashboards. Start with patient questions. They don’t say “supply

An investigative report on how large language models misrepresent prescription drugs, what that costs manufacturers, and why most brand teams

A look at the $50B opportunity reshaping how pharma companies launch, monitor, and defend their brands in the age of

Spend enough time watching patient questions, and a pattern emerges: people aren’t just asking what works—they’re asking what they can

Scroll through enough patient questions and a pattern emerges: people aren’t just taking drugs—they’re tuning them. Combining, stretching, substituting. Off-label

If you want to understand how patients actually think about switching between similar drugs, don’t look for clean “Drug A

Physicians are increasingly asking AI chatbots how to dose drugs, manage contraindications, and choose between therapies. The AI answers. The

The pharmaceutical industry has spent decades building brand reputations through clinical trials, physician detailing, and tightly controlled messaging. That infrastructure

If you want to know when adherence breaks, don’t look at refill data. That’s the autopsy. The early signals show

Why Pharmaceutical Brands Must Shift from Social Listening to AI Monitoring — Before Regulators Do The clinical detail rep used

How large language models are quietly reshaping brand exposure, regulatory liability, and the future of pharmacovigilance The alert came from